- A significant minority of patients with COPD have favorable response to corticosteroid treatment. In addition, the benefit of corticosteroid treatment may be outweighed by the side effects. Long-term administration of inhaled steroids is a safe means of treatment. We hypothesized that treatment with high-dose inhaled budesonide would improve clinical symptoms and pulmonary function in subjects with COPD, and that the response to inhaled β2-agonist will serve to individualize steroid responders. We compared a 6-week course of 800 µg/d inhaled budesonide with placebo, separated by 4 weeks when no medication was taken, in a double-blind crossover trial, in 8 patients responding to inhaled β2-agonist, and in 22 nonresponders with stable COPD. In six of eight “responders to p2-agonist,” there was a significant improvement in the FEV1 (defined as ≥20%) following inhaled budesonide, as compared with placebo. In the 22 “nonresponders to p2-agonist,” there was no significant improvement in the mean FEV1 (1.41±0.1 L before, and 1.61±0.1 L after treatment) with inhaled budesonide or placebo. Over the 6-week course of treatment by either budesonide or placebo, the nonresponders reported similar β2-agonist consumption (4.8±0.2 and 5.0±0.1 puffs per patient per day, respectively). However, there was a significant difference between the two periods of treatment in the responders as for the mean daily number of β2-agonist inhalations (2.4±0.1 in the budesonide period as compared with 5.3 ±0.1 in the placebo period; p<0.005). We conclude that treatment with inhaled steroids improved spirometry data and inhaled β2-agonist consumption in about 25% of patients with stable COPD, and this rate is increased to about 75% in patients who respond to β2-agonist inhalation.